Author Correction: Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril

N. Ferri, A. Corsini, R. Pontremoli

Department of Medicine, University of Padua, Padua, Italy

---

• Nephrology

Correction to: European Review for Medical and Pharmacological Sciences 2022; 26 (20): 7482–7492. DOI: 10.26355/eurrev_202210_30018-PMID: 36314318, published online on October 28, 2022.

After publication, the authors applied some corrections to the text:

– The section “Clinical Oharmacology of Lercanidipine” has been corrected into “Clinical Pharmacology of Lercanidipine”

– The Legend of Figure 2 has been corrected as follows: Ca T-type channels vs. Ca L-type channels selectivity ratio. LAC, lacidipine, AML, amlodipine; MIB, mibefradil; LER, lercanidipine; *p<0.05, ** p<0.01 vs. LAC (low concentrations); †p<0.01 LAC vs. all other CCBs (high concentrations). Source: Modified from 25.

– The reference 25 has been changed into: Hart P, Bakris GL. Calcium antagonists: Do they equally protect against kidney injury? Kidney Int 2008; 73: 795-796.

There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.

Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril

Free PDF Download